by | Apr 23, 2024 | Lupus Foundation of America, News & Events
A first person has been dosed with the investigational therapy, AlloNK® (also known as AB-101) for treatment of lupus nephritis, (LN, lupus-related kidney disease). This is the first time a person in the US has received an allogeneic NK cell (natural killer cell, a...
by | Apr 20, 2024 | Lupus Foundation of America, News & Events
A new study published in Lupus Science & Medicine found a new diagnostic and disease activity monitoring biomarker for systemic lupus erythematosus (SLE) which could help understand pathogenesis, identify therapeutic targets, and guide clinical management. In the...
by | Apr 19, 2024 | Lupus Foundation of America, News & Events
The U.S. Food & Drug Administration has granted approval for a Phase 1 study to evaluate the safety and efficacy of investigational therapy, CB-010, for treatment of lupus nephritis (LN). The GALLOP study will begin by year-end and will also be evaluated for...
by | Apr 17, 2024 | Lupus Foundation of America, News & Events
Understanding the immune cells that spur inflammation in lupus nephritis (LN) can help advance knowledge of disease progression and identify new treatments. A new study discovered that macrophages, a type of white blood cells that attack and destroy diseased and...
by | Apr 11, 2024 | Lupus Foundation of America, News & Events
Incorporating physical activity and exercise can help improve health outcomes and quality of life for people living with systemic lupus erythematosus (SLE). Recently, an international task force provided the first set of recommendations for physical activity that...
by | Apr 5, 2024 | Lupus Foundation of America
Karleen’s journey with lupus began in the summer of 1983 when she received her lupus diagnosis, although her symptoms first began appearing as early as 1982 during her freshman year of college. Mouth sores and knee swelling were the initial signs, gradually...